Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus

Annals of Clinical Microbiology and Antimicrobials
Benjamin H GernXuan Qin

Abstract

In vitro trends of cefazolin and ceftriaxone susceptibilities from pediatric clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) between 2011 and 2016 were analyzed for surveillance. Our laboratory continues to use agar disk diffusion for staphylococcal susceptibilities applying Clinical Laboratory Standard Institute's 2012 breakpoints. A total of 3992 MSSA clinical isolates in the last 6 years were analyzed for their in vitro cefazolin and ceftriaxone susceptibilities. While all MSSA isolates exhibited cefazolin susceptibilities within the "susceptible" zone range, there have been a proportion of isolates with ceftriaxone susceptibilities falling in "intermediate" zones, ranging from 2.6% in 2011 to 8.3% in 2016. Cefazolin continues to be the recommended agent for MSSA treatment at our institution, reflected by the finding that only 2% (6/321) of patients who received ceftriaxone as definitive therapy for MSSA bacteremia during the study period. We have confirmed the cefoxitin-predicted MSSA susceptibility to cefazolin, but have found concerning drifts in ceftriaxone susceptibilities by continued in vitro monitoring over the last 6 years.

References

Apr 11, 2001·Emerging Infectious Diseases·H F Chambers
Apr 4, 2003·The New England Journal of Medicine·Soju ChangUNKNOWN Vancomycin-Resistant Staphylococcus aureus Investigative Team
Jul 1, 1961·Journal of Clinical Pathology·M BARBER
Nov 16, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M PaulJ Bishara
Dec 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brent W WielandJonas Marschall
Jan 25, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jennifer Dien BardBrandi Limbago
Nov 19, 2014·Antimicrobial Agents and Chemotherapy·Kady PheVincent H Tam

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Manuel L Fernández-Guerrero, Miguel de Górgolas
The Journal of Infectious Diseases
R H EngP Scadutto
© 2022 Meta ULC. All rights reserved